Download PDF
Thromb Haemost 1979; 42(03): 994-1008
DOI: 10.1055/s-0038-1656990
Original Article
Schattauer GmbH Stuttgart

An Acquired Abnormal Fibrinogen Associated with Thromboembolic Disease and Pseudotumor Cerebri

Leo D’Souza
The Department of Internal Medicine, Hematology-Oncology Division and Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio
,
Macie C Coots
The Department of Internal Medicine, Hematology-Oncology Division and Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio
,
Helen I Glueck
The Department of Internal Medicine, Hematology-Oncology Division and Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio
› Author Affiliations
Further Information

Publication History

Submitted May 1978

Accepted 22 July 1978

Publication Date:
23 August 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

An abnormal fibrinogen was found in a patient associated with disabling recurrent phlebitis and pulmonary emboli, pseudotumor cerebri, gout and endometriosis. The fibrinogen is characterized by (1) abnormal side-to-side and end-to-end polymerization, (2) abnormal fibrinopeptide release, (3) a delayed γ-γ dimerization of the non cross-linked fibrin, (4) a pH optimum of 7-7.8, and (5) a deviation from normal amino acid composition with regard to lysine, aspartic acid, glutamic acid and serine. Since no defect has been found in any of her three children, and since the prothromin and partial thromboplastin times vary from time to time, it is assumed that the defect is acquired. Liver disease, usually associated with acquired abnormal fibrinogen, has been excluded as an etiological cause since liver function tests and biopsy are completely normal.

 

  • References

  • 1 Aiäch M, Rogé J, Busy MF, Durand H, Guéroult N, Chanrion Ch, Leclerc M, Justin-Besançon L. 1973; Dysfibrinogénémies acquises et affection hépatiques. A propos, de 30 observations. Sem Hop Paris 49 (03) 183
    PubMedGoogle Scholar
  • 2 Al-Mondhiry HA B, Bilezikian SB, Nossel HL. 1975; Fibrinogen “New York”: An abnormal fibrinogen associated with thromboembolism: Functional evaluation. Blood 45: 607
    CrossrefPubMedGoogle Scholar
  • 3 Beck EA, Carache P, Jackson DP. 1964; An inherited coagulation disorder caused by an abnormal fibrinogen: Fibrinogen Baltimore. Nature 208: 143
    PubMedGoogle Scholar
  • 4 Beck EA, Shainoff JR, Vogen A, Jackson DP. 1971; Functional evaluation of an inherited abnormal fibrinogen: Fibrinogen Baltimore. Journal of Clinical Investigation 50: 1874
    CrossrefPubMedGoogle Scholar
  • 5 Bergstöm K, WalléN P. 1961; Removal of contaminating plasminogen from purified bovine fibrinogen. Arkiv Kemi 17: 503
    PubMedGoogle Scholar
  • 6 Blombäck B, BlombäcK M. 1956; Purification of human and bovine fibrinogen. Arkiv Kemi 10: 415
    PubMedGoogle Scholar
  • 7 Boyer MH, Shainoff JR, Ratnoff OD. 1972; Acceleration of fibrin polymerization by calcium ions. Blood 39: 382
    PubMedGoogle Scholar
  • 8 Brown Ill CH, Crowe MF. 1975; Defective polymerization in the conversion of fibrinogen Baltimore to fibrin. Journal of Clinical Investigation 55: 1190
    CrossrefPubMedGoogle Scholar
  • 9 Burmester HB C, Aulton K, Horsfield GI. 1970; Evaluation of a rapid method for the determination of plasma fibrinogen. American Journal of Clinical Pathology 23: 43
    CrossrefPubMedGoogle Scholar
  • 10 Cartwright T, Kekwick RG O. 1971; A comparative study of human, cow, pig and sheep fibrinogen. Biochimica et Biophysica Acta 236: 550
    CrossrefPubMedGoogle Scholar
  • 11 Davis BJ. 1964; Disc electrophoresis method and application to human serum proteins. Annals of the New York Academy of Sciences 121: 404
    PubMedGoogle Scholar
  • 12 Donaldson VH, Kisker CT, Greive M, Rush R, Mackenzie MR. 1972. Defective thrombin-fibrinogen interaction with intermittent dysfibrinogenemia. Proceedings 3rd Congress of the International Society on Thrombosis and Haemostasis. Washington: p 82
    Google Scholar
  • 13 Doolittle RF. 1973; Structural aspects of the fibrinogen to fibrin conversion. Advances in Protein Chemistry 27: 2
    PubMedGoogle Scholar
  • 14 Dunker AK, Rueckert RR. 1969; Observations on molecular weight determinations on polyacrylamide gel. Journal of Biological Chemistry 244: 5074
    PubMedGoogle Scholar
  • 15 Egeberg O. 1967; Inherited fibrinogen abnormality causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 17: 176
    PubMedGoogle Scholar
  • 16 Von Felten A, Straub PW, Frick PG. 1969; Dysfibrinogenemia in a patient with primary hepatoma. New Engl. Journal of Medicine 280 (08) 405
    PubMedGoogle Scholar
  • 17 Flute PT. 1977; Disorders of plasma fibrinogen synthesis. British Medical Bulletin 33: 253
    CrossrefPubMedGoogle Scholar
  • 18 Forman WB, Ratnoff O, Boyer MH. 1968; An inherited qualitative abnormality in plasma fibrinogen: Fibrinogen Cleveland. Journal of Laboratory and Clinical Medicine 72: 455
    PubMedGoogle Scholar
  • 19 Foster JB, De Natale A, Dotti LB. 1959; Determination of plasma fibrinogen by means of centrifugation after heating. American Journal of Clinical Pathology 31: 42
    CrossrefPubMedGoogle Scholar
  • 20 Gralnick HR, Finlayson JS. 1972; Congenital dysfibrinogenemias. Annals of Internal Medicine 77: 471
    CrossrefPubMedGoogle Scholar
  • 21 Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS. 1971; Fibrinogen Bethesda: A congenital dysfibrinogenemia with delayed fibrinopeptide release. Journal of Clinical Investigation 50: 1819
    CrossrefPubMedGoogle Scholar
  • 22 Gray WR. 1972. Methods in Enzymology. In Hirs CH W, TIMASHEFF SN. (ed.) Dansyl Chloride Procedure. Academic Press; N. Y: Vol. XXVB, p. 139
    Google Scholar
  • 23 Gruppo RA, Glueck HI, Granger SU, Miller MA. 1977; Platelet function in sickle cell anemia. Thrombosis Research 10: 325
    CrossrefPubMedGoogle Scholar
  • 24 Hampton JW, Garrison D. 1972; Fibrinogen and fibrin stabilizing factor. Medical Clinics of North America 56 (01) 133
    CrossrefPubMedGoogle Scholar
  • 25 Jackson DP, Beck EA, Charache P. 1965; Congenital disorders of fibrinogen. Federation Proceedings 24: 816
    PubMedGoogle Scholar
  • 26 Jackson DP, Beck EA. 1970. Inherited Abnormal Fibrinogen. In Brinkhous K. (ed.) Hemophilia and New Hemorrhagic States. U. N. C. Press; Chapel Hill: p 225
    Google Scholar
  • 27 Krantz S, Lober M. 1976; Übersicht angeborener und erworbener Varianten des Plasmafibrinogens. Folia Haematol, Leipzig 103 (06) 793
    PubMedGoogle Scholar
  • 28 Lane DA, Scully MF, Thomas DP, Kakkar VV, Woolf IL, Williams R. 1977; Acquired dysfibrinogenemia in acute and chronic liver disease. British Journal of Haematology 35: 301
    CrossrefPubMedGoogle Scholar
  • 29 Langdell RW, Wagner RH, Brinkhous KM. 1964. Estimation of antihemophiliac activity by the partial thromboplastin technic. In Tocantins LM, Kazal LA. (ed.) Blood Coagulation, Hemorrhage and Thrombosis. Gruñe and Stratton; New York: p 103
    Google Scholar
  • 30 Lewis R, Glueck HI. 1958; A micro method for determining clotting times using capillary blood and siliconized tubes. Journal of Laboratory and Clinical Medicine 52: 299
    PubMedGoogle Scholar
  • 31 Lipinska L, Lipinski B, Gurewich M, Hoffmann KD. 1976; Fibrinogen heterogenity in cancer, in occlusive vascular disease and after surgical problems. American Journal of Clinical Pathology 66: 598
    CrossrefPubMedGoogle Scholar
  • 32 Liu IY, Chang YH. 1971; Hydrolysis of proteins with p-toluene sulfonic acid: Determination of tryptophan. Journal of Biological Chemistry 246: 2842
    PubMedGoogle Scholar
  • 33 Lorand L. 1952; Fibrinopeptides. Biochemical Journal 52: 200
    CrossrefPubMedGoogle Scholar
  • 34 Mammen FF. Congenital abnormalities of the fibrinogen molecule. 1974; Seminars in Thrombosis and Hemostasis 1: 184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Marder VJ. 1976; The functional defects of hereditary dysfibrinogens. Thrombosis and Hamostasis 36: 1
    PubMedGoogle Scholar
  • 36 McKee PA, Matlock P, Hill RL. 1970; Subunit structure of human fibrinogen, soluble fibrin and cross-linked insoluble fibrin. Proceedings of National Academy of Sciences (U. S.) 66: 738
    CrossrefPubMedGoogle Scholar
  • 37 Ménaché D. 1973; Abnormal fibrinogens. A Review. Thrombosis et Diathesis Haemorrhagica 29: 525
    PubMedGoogle Scholar
  • 38 Morse D, Horecker BL. 1966; Thin-layer chromatographic separation of DNS amino acids. Analytical Biochemistry 14: 429
    CrossrefPubMedGoogle Scholar
  • 39 Mosesson MW, Beck EA. 1969; Chromatographic, ultracentrifugal, and related studies of fibrinogen “Baltimore”. Journal of Clinical Investigation 48: 1656
    CrossrefPubMedGoogle Scholar
  • 40 Murano G. 1974; Molecular Structure of Fibrinogen. Seminars in Thrombosis and Hemostasis 1: 1
    PubMedGoogle Scholar
  • 41 Nussbaum M, Morse B. 1964; Plasma fibrin stabilizing factor in various diseases. Blood 23: 669
    PubMedGoogle Scholar
  • 42 Ornstein L. 1964; Disc Electrophoresis I: Background and Theory. Annals of the New York Academy of Sciences 121: 321
    PubMedGoogle Scholar
  • 43 Ponari O, Pou R. 1975; Le dysfibrinogénémie congenite et acquisite. Haematologica 60 (17) 96
    PubMedGoogle Scholar
  • 44 Quick AJ. 1945; On the quantitiative estimation of prothrombin. American Journal of Clinical Pathology 15: 560
    CrossrefPubMedGoogle Scholar
  • 45 Ratnoff O, Forman WB. 1976; Criteria for the differentiation of dysfibrinogénémie states. Seminars in Hematology 13 (02) 141
    PubMedGoogle Scholar
  • 46 Ratnoff O, Menzie C. 1951; A new method for determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 37: 316
    PubMedGoogle Scholar
  • 47 Samama M, Soria J, Soria C, Bousser J. 1969; Dysfibrinogénèmie congénitale et familiale sans tandance hémorragique. Nouvelle Revue Française d’Hematologie 9: 817
    PubMedGoogle Scholar
  • 48 Sherman LA, Mosesson MW, Sherry S. 1969; Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction 1-4. Biochemistry 8: 1515
    CrossrefPubMedGoogle Scholar
  • 49 Soria J, Coupier J, Samama M, Fixier P, Bilski-Pasquier G. 1968. Dysfibrinogenemia without bleeding tendency with abnormal polymerization of fibrin monomers in a case of severe hepatitis. XII Congress International Society of Hematology. New York: p 180
    Google Scholar
  • 50 Soria J, Soria C, Samama M, Coupier J, Girard ML, Bousser J, Bliski-Pasquier G. 1970; Dysfibrinogénémias acquises dans les atteintes hépatiques sévères. Coagulation 3 (01) 37
    PubMedGoogle Scholar
  • 51 Soulier JP. 1959; La bentonite, nouvelle absorbant des facteurs des coagulation. Revue Française d’études Cliniques at Biologiques 4 (02) 153
    PubMedGoogle Scholar
  • 52 Stander RW, Flessa HC, Glueck HI, Kisker T. 1971; Changes in maternai coagulation factors after intra-amnionic injection of hypertonie saline. Obstetrics and Gynecology 31: 660
    PubMedGoogle Scholar
  • 53 Verhaeghe R, Van Damme B, Molla A, Vermylin J. 1972; Dysfibrinogenemia associated with primary hepatoma. Scandinavian Journal of Haematology 9: 451
    PubMedGoogle Scholar
  • 54 Verstraete M. 1970; Discussion. Thrombosis et Diathesis Haemorrhagica 29 Supplement 334
    PubMedGoogle Scholar
  • 55 Weber K, Osborn M. 1969; The reliability of molecular weight determinations by dodecyl sulfate polyacrylamide gel electrophoresis. Journal Biological Chemistry 244: 4406
    PubMedGoogle Scholar